372 related articles for article (PubMed ID: 23792029)
21. Hepatitis B s antigen kinetics during treatment with nucleos(t)ides analogues in patients with hepatitis B e antigen-negative chronic hepatitis B.
Striki A; Manolakopoulos S; Deutsch M; Kourikou A; Kontos G; Kranidioti H; Hadziyannis E; Papatheodoridis G
Liver Int; 2017 Nov; 37(11):1642-1650. PubMed ID: 28345181
[TBL] [Abstract][Full Text] [Related]
22. Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study).
Hirode G; Choi HSJ; Chen CH; Su TH; Seto WK; Van Hees S; Papatheodoridi M; Lens S; Wong G; Brakenhoff SM; Chien RN; Feld J; Sonneveld MJ; Chan HLY; Forns X; Papatheodoridis GV; Vanwolleghem T; Yuen MF; Hsu YC; Kao JH; Cornberg M; Hansen BE; Jeng WJ; Janssen HLA;
Gastroenterology; 2022 Mar; 162(3):757-771.e4. PubMed ID: 34762906
[TBL] [Abstract][Full Text] [Related]
23. Relevance of hepatitis B surface antigen levels in patients with chronic hepatitis B during 5 year of tenofovir treatment.
Singh AK; Sharma MK; Hissar SS; Gupta E; Sarin SK
J Viral Hepat; 2014 Jun; 21(6):439-46. PubMed ID: 24750522
[TBL] [Abstract][Full Text] [Related]
24. Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely.
Chevaliez S; Hézode C; Bahrami S; Grare M; Pawlotsky JM
J Hepatol; 2013 Apr; 58(4):676-83. PubMed ID: 23219442
[TBL] [Abstract][Full Text] [Related]
25. Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy.
Bazinet M; Pântea V; Placinta G; Moscalu I; Cebotarescu V; Cojuhari L; Jimbei P; Iarovoi L; Smesnoi V; Musteata T; Jucov A; Dittmer U; Krawczyk A; Vaillant A
Gastroenterology; 2020 Jun; 158(8):2180-2194. PubMed ID: 32147484
[TBL] [Abstract][Full Text] [Related]
26. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA.
Chan HL; Chan CK; Hui AJ; Chan S; Poordad F; Chang TT; Mathurin P; Flaherty JF; Lin L; Corsa A; Gaggar A; Subramanian GM; McHutchison JG; Lau G; Lee S; Gane EJ
Gastroenterology; 2014 May; 146(5):1240-8. PubMed ID: 24462735
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
Lok AS; Trinh H; Carosi G; Akarca US; Gadano A; Habersetzer F; Sievert W; Wong D; Lovegren M; Cohen D; Llamoso C
Gastroenterology; 2012 Sep; 143(3):619-628.e1. PubMed ID: 22643350
[TBL] [Abstract][Full Text] [Related]
28. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues.
Yip TC; Wong GL; Chan HL; Tse YK; Lam KL; Lui GC; Wong VW
J Hepatol; 2019 Mar; 70(3):361-370. PubMed ID: 30367899
[TBL] [Abstract][Full Text] [Related]
29. Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study.
Zoulim F; Carosi G; Greenbloom S; Mazur W; Nguyen T; Jeffers L; Brunetto M; Yu S; Llamoso C
J Hepatol; 2015 Jan; 62(1):56-63. PubMed ID: 25176615
[TBL] [Abstract][Full Text] [Related]
30. [Efficacy of 48-week tenofovir disoproxil fumarate therapy in patients who were unresponsive to nucleoside-analogue treatments].
Huang M; Li X; Wu Y; Tao L; Jie Y; Li X; Shi H; Lin G; Yang F; Ao Y; Pang Y; Zhang M; Chong Y
Zhonghua Gan Zang Bing Za Zhi; 2014 Apr; 22(4):266-71. PubMed ID: 25173224
[TBL] [Abstract][Full Text] [Related]
31. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
[TBL] [Abstract][Full Text] [Related]
32. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir.
Hadziyannis SJ; Sevastianos V; Rapti I; Vassilopoulos D; Hadziyannis E
Gastroenterology; 2012 Sep; 143(3):629-636.e1. PubMed ID: 22659218
[TBL] [Abstract][Full Text] [Related]
33. Tenofovir disoproxil fumarate monotherapy maintains HBV suppression achieved by a "de novo" combination of lamivudine-adefovir: a pilot study.
Ruggiero G; Marrone A; Rainone I; Boemio A; Adinolfi LE; Pasquale G; Rinaldi L; Guerrera B; Andreana L; Zampino R;
Infez Med; 2016 Dec; 24(4):278-286. PubMed ID: 28011962
[TBL] [Abstract][Full Text] [Related]
34. Trajectories of serum hepatitis B surface antigen kinetics in patients with chronic hepatitis B receiving long-term nucleos(t)ide analogue therapy.
Hsu WF; Chen CF; Lai HC; Su WP; Lin CH; Chuang PH; Chen SH; Chen CH; Wang HW; Huang GT; Peng CY
Liver Int; 2018 Apr; 38(4):627-635. PubMed ID: 28857411
[TBL] [Abstract][Full Text] [Related]
35. Kinetics and prediction of HBsAg loss during long-term therapy with nucleos(t)ide analogues of different potency in patients with chronic hepatitis B.
Li MR; Xi HL; Wang QH; Hou FQ; Huo N; Zhang XX; Li F; Xu XY
PLoS One; 2014; 9(6):e98476. PubMed ID: 24905586
[TBL] [Abstract][Full Text] [Related]
36. Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial.
de Niet A; Jansen L; Stelma F; Willemse SB; Kuiken SD; Weijer S; van Nieuwkerk CMJ; Zaaijer HL; Molenkamp R; Takkenberg RB; Koot M; Verheij J; Beuers U; Reesink HW
Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):576-584. PubMed ID: 28522204
[TBL] [Abstract][Full Text] [Related]
37. HBsAg loss after peginterferon-nucleotide combination treatment in chronic hepatitis B patients: 5 years of follow-up.
Stelma F; van der Ree MH; Jansen L; Peters MW; Janssen HLA; Zaaijer HL; Takkenberg RB; Reesink HW
J Viral Hepat; 2017 Dec; 24(12):1107-1113. PubMed ID: 28632898
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials.
Buti M; Wong DK; Gane E; Flisiak R; Manns M; Kaita K; Janssen HLA; Op den Brouw M; Jump B; Kitrinos K; Crans G; Flaherty J; Gaggar A; Marcellin P
Lancet Gastroenterol Hepatol; 2019 Apr; 4(4):296-304. PubMed ID: 30795958
[TBL] [Abstract][Full Text] [Related]
39. Serum HBsAg kinetics and usefulness of interferon-inducible protein 10 serum in HBeAg-negative chronic hepatitis B patients treated with tenofovir disoproxil fumarate.
Papatheodoridis G; Triantos C; Hadziyannis E; Zisimopoulos K; Georgiou A; Voulgaris T; Vlachogiannakos I; Nikolopoulou V; Manolakopoulos S
J Viral Hepat; 2015 Dec; 22(12):1079-87. PubMed ID: 26146764
[TBL] [Abstract][Full Text] [Related]
40. Predicting HBsAg clearance in genotype A chronic hepatitis B using HBsAg epitope profiling: A biomarker for functional cure.
Walsh R; Hammond R; Yuen L; Deerain J; O'Donnell T; Leary T; Cloherty G; Gaggar A; Kitrinos K; Subramanian M; Wong D; Locarnini S
Liver Int; 2019 Nov; 39(11):2066-2076. PubMed ID: 31379058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
